Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

Aurinia Pharmaceuticals (AUPH) shares ended the last trading session 7.5% higher at $8.63. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 0.6% gain over the past four weeks.The sudden price rise can be attributable to positive investor expectations for Lupkynis, the company’s sole marketed drug, which is approved for the treatment of adults with active lupus nephritis (LN). Lupkynis sales increased 25% year over y ...